The statements below are Rochon Genova’s account of this case. They reflect allegations or the firm’s position and have not been determined by a court unless a settlement or judgment is noted.
Latest update
On December 23, 2024 , the Ontario Superior Court of Justice approved settlement.
Source: Rochon Genova
About This Case
This class action, filed in the Ontario Superior Court of Justice, alleged that the pharmaceutical companies responsible for manufacturing and marketing Abilify and Abilify Maintena—Bristol-Myers Squibb, Otsuka Pharmaceuticals, and Lundbeck—knew, or ought to have known, that these drugs cause or materially increase the risk of compulsive behaviours:
compulsive gambling, compulsive shopping, hypersexuality and binge eating.
The claim further alleged that the companies failed to adequately warn Canadian patients and healthcare providers of these risks, resulting in significant harm to the plaintiffs and proposed class members.
Source: Rochon Genova
Disclaimer: This information is sourced from Rochon Genova. It is provided for general information only and does not constitute legal advice. Always verify details with the original source before taking any action.
Legal disclaimer: Information on this page is general in nature and does not constitute legal advice. ClaimBar tracks class action settlements and provides updates. Always seek professional legal advice for your specific circumstances.
Did this page answer your question?